- Aflibercept, sold
under the
brand names Eylea and Zaltrap, is a
medication used to
treat wet
macular degeneration and
metastatic colorectal cancer. It...
- " In 2011, Regeneron's
first successful drug was
Eylea for age-related
macular degeneration.
Eylea prevented leaky blood vessels in the eye from causing...
- May 2024 aflibercept-yszy/Opuviz aflibercept/
Eylea May 2024 aflibercept-jbvf/Yesafili aflibercept/
Eylea May 2024 eculizumab-aeeb/Bkemv eculizumab/Soliris...
-
occlusion Branch retinal artery occlusion Branch retinal vein
occlusion Eylea Iridodialysis Ischemic optic neuropathy Ophthalmology at a Glance, Jane...
-
autoinflammatory conditions.
Approved by the FDA in
February 2008.[citation needed]
Eylea (aflibercept injection) was
approved by the U.S. Food and Drug Administration...
-
exifone (INN)
exiproben (INN) Exna
Exosurf Neonatal Exsel Extra-Strength Aim
Extraneal Exxua Exzolt Eylea HD
ezatiostat (USAN, INN)
ezogabine (USAN)...
-
edema caused by
diabetes and/or
retinal vein occlusion. On July 29, 2014,
Eylea (aflibercept), an
intravitreal injection produced by
Regeneron Pharmaceuticals...
- 6750 7298 11
rivaroxaban anticoagulant Xarelto 6589 6234 12
aflibercept Eylea 6551 5830 13
infliximab Remicade 5908 7152 14
Pneumococcal conjugate vaccine...
- In 2019,
identified "key growth"
products were
Xarelto (rivaroxaban),
Eylea (aflibercept),
Stivarga (regorafenib),
Xofigo (radium-223), and Adempas...
-
remains more costly, as is the more
recent (approved in 2011)
aflibercept (
Eylea).
Tests on
these treatments are
ongoing relative to the
efficacy of one...
